We do our best to actualize our hopes and dreams for humankind: ‘perpetual youth’ and ‘a lifetime of health’. The results of such effort are continued with ‘Completion of KOREF’, ‘First completion for genome map as a Korean,’ ‘World’s first completed genome map for tiger, whale, horse, leopard,’ ‘Release of a high-speed, automatic liquid biopsy product,’ ‘CD-PRIME’ and ‘Certification of new medical technology and permit for Class 3 for AmoyDx ROS1 mutations detection kit from the Ministry of Food and Drug Safety’. We aim to become ‘a global company specializing in analyzing genomics based on genome ICT’ by working on mankind’s task of early diagnosis and prediction of cancer, selective prediction of rare diseases and treatment of genetic disorders with precision medicine.
We continue to challenge the development of new analytical technologies such as AI (Artificial Intelligence) algorithm and Multi-Omics. We have established a cooperative system with world-class scholars such as George McDonald Church and Prashant Gulab Ram Mali to secure global competitiveness in the genetic analysis market.
Through this cooperative system, the company will provide services in ‘Early diagnosis for cancer/diseases’, ‘Medical and health care’, ‘Customized precision medicine’, and ‘Gene therapy’.
Thank you from Clinomics Executives.